Abstract
British Journal of DermatologyVolume 145, Issue 6 p. 1027-1028 The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis B. Kirby, B. Kirby Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorM.J. Boffa, M.J. Boffa Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorN. Nayak, N. Nayak Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorW.M. Gallatin, W.M. Gallatin Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorS. Martin, S. Martin Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorC.E.M. Griffiths, C.E.M. Griffiths Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this author B. Kirby, B. Kirby Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorM.J. Boffa, M.J. Boffa Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorN. Nayak, N. Nayak Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorW.M. Gallatin, W.M. Gallatin Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorS. Martin, S. Martin Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this authorC.E.M. Griffiths, C.E.M. Griffiths Dermatopharmacology Unit, Dermatology Centre, Irving Building, University of Manchester, Hope Hospital, Salford, Manchester, M6 8HD, U.K.*ICOS Corporation, Bothell, Washington, U.S.A.†Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany E-mail: christopher.griffiths@man.ac.ukSearch for more papers by this author First published: 23 December 2001 https://doi.org/10.1046/j.1365-2133.2001.04487.xCitations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume145, Issue6December 2001Pages 1027-1028 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
